Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nigel Fleming Insider Profile
4 Followers
Nigel Fleming, Director at Amneal Pharmaceuticals, holds 8.20K shares in Amneal Pharmaceuticals (Ticker: AMRX). Most recently, Nigel Fleming Sold $29,166 shares of Amneal Pharmaceuticals on Sep 01, 2015 for an estimated value of 1.20M.
Profitable Transactions
1 out of 4 Profitable Transactions
Average Return
-42.90%
Average return per transaction
Time Frame
Compare to
Insider Roles
Director
Roles that Nigel Fleming holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Sep 01, 2015 - Sep 01, 2016
Return:+41.00%
The most profitable trade made by Nigel Fleming
Nigel Fleming's Trading History
List of latest transactions for each holding click on a transaction to see Nigel Fleming's performance on stock
You May Also Like
Nigel Fleming insider profile FAQ
What is the percentage of profitable transactions made by Nigel Fleming?
The percentage of profitable transactions made by Nigel Fleming is 25%.
What is the average return per transaction made by Nigel Fleming?
The average return per transaction made by Nigel Fleming is -42.90%.
What stocks does Nigel Fleming hold?
Nigel Fleming holds: AMRX stocks.
What was Nigel Fleming’s latest transaction?
Nigel Fleming latest transaction was an Informative Sell of $1.20M.
What was Nigel Fleming's most profitable transaction?
Nigel Fleming’s most profitable transaction was an Informative Sell of AMRX stock on September 1, 2015. The return on the trade was 41.00%.
What is Nigel Fleming's role in Amneal Pharmaceuticals?
Nigel Fleming's role in Amneal Pharmaceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.